EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Outcomes in patients with ETV6 :: RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies

Katelyn Purvis iD, Yinmei Zhou, Seth E Karol iD, Jeffrey E Rubnitz iD, Raul C Ribeiro iD, Shawn Lee, Jun J Yang, W Paul Bowman, Lu Wang iD, Stephanie B Dixon iD, Kathryn G Roberts iD, Qingsong Gao iD und 5 weitere

Blood · 2025

DOI: 10.1182/blood.2024024936 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Blood, 2025. Verfasst von Katelyn Purvis und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, ETS Translocation Variant 6 Protein, Oncogene Proteins, Fusion, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Children with ETV6::RUNX1 or high-hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients low risk, regardless of their National Cancer Institute (NCI) risk classification, except when there is slow minimal residual disease (MRD) response or central nervous system/testicular involvement. We analyzed outcomes in children (aged 1-18.99 years) with these genotypes in the SJ Total XV/XVI studies (2000-2017). Patients with ETV6::RUNX1 (n = 222) or high-hyperdiploid (n = 296) B-ALL had 5-year event-free survival (EFS) of 97.7% ± 1.1% and 94.7% ± 1.4%, respectively. For ETV6::RUNX1, EFS was comparable between NCI standard-risk and high-risk patients and between SJ low-risk and standard-risk patients. Of the 40 NCI high-risk patients, 37 who received SJ low-risk therapy had excellent EFS (97.3% ± 2.8%). For high-hyperdiploid B-ALL, NCI high-risk patients had worse EFS than standard-risk patients (87.6% ± 4.5% vs 96.4% ± 1.3%; P = .016). EFS was similar for NCI standard-risk and high-risk patients classified as SJ low risk (96.0% ± 1.5% and 96.9% ± 3.2%; P = .719). However, EFS was worse for NCI high-risk patients than for NCI standard-risk patients receiving SJ standard/high-risk therapy (77.4% ± 8.2% vs 98.0% ± 2.2%; P = .004). NCI high-risk patients with ETV6::RUNX1 or high-hyperdiploid B-ALL who received SJ low-risk therapy had lower incidences of thrombosis (P = .013) and pancreatitis (P = .011) than those who received SJ standard/high-risk therapy. MRD-directed therapy yielded excellent outcomes, except for NCI high-risk high-hyperdiploid B-ALL patients with slow MRD response, who require new treatment approaches. Among NCI high-risk patients, 93% with ETV6::RUNX1 and 54% with high-hyperdiploid B-ALL experienced excellent outcomes with a low-intensity regimen. These trials were registered at www.clinicaltrials.gov as #NCT00137111 and #NCT00549848.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Core Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-etsAdolescentChildChild, PreschoolFemaleHumansInfantMaleNeoplasm, ResidualRepressor ProteinsTreatment Outcome

Substanzen

Core Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinOncogene Proteins, FusionProto-Oncogene Proteins c-etsRepressor ProteinsRUNX1 protein, humanTEL-AML1 fusion protein

Autor:innen und Institutionen

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
  • Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore.
  • Department of Pediatrics, Cook Children's Medical Center, Fort Worth, TX.

ORCID-Profile: Katelyn Purvis, Seth E Karol, Jeffrey E Rubnitz, Raul C Ribeiro, Lu Wang, Stephanie B Dixon, Kathryn G Roberts, Qingsong Gao, Charles G Mullighan, Ching-Hon Pui, Hiroto Inaba

Förderung

  • NCI NIH HHS

Zitieren

APA

Purvis, K., Zhou, Y., Karol, S. E., Rubnitz, J. E., Ribeiro, R. C., Lee, S., Yang, J. J., Bowman, W. P., Wang, L., Dixon, S. B., Roberts, K. G., Gao, Q., Cheng, C., Mullighan, C. G., Jeha, S., Pui, C. H., & Inaba, H. (2025). Outcomes in patients with ETV6 :: RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies. Blood. https://doi.org/10.1182/blood.2024024936

Vancouver

Purvis K, Zhou Y, Karol SE, Rubnitz JE, Ribeiro RC, Lee S, et al. Outcomes in patients with ETV6 :: RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies. Blood. 2025. doi:10.1182/blood.2024024936

BibTeX
@article{Purvis2025,
  author = {Purvis, Katelyn and Zhou, Yinmei and Karol, Seth E and Rubnitz, Jeffrey E and Ribeiro, Raul C and Lee, Shawn and Yang, Jun J and Bowman, W Paul and Wang, Lu and Dixon, Stephanie B and Roberts, Kathryn G and Gao, Qingsong and Cheng, Cheng and Mullighan, Charles G and Jeha, Sima and Pui, Ching-Hon and Inaba, Hiroto},
  title = {Outcomes in patients with ETV6 :: RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies},
  journal = {Blood},
  year = {2025},
  doi = {10.1182/blood.2024024936}
}
Kostenlos starten →